SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is seeing intense volatility following its earnings report, where shares initially slid on a slight fourth-quarter revenue guidance miss before recovering sharply as management highlighted massive AI revenue projections for fiscal 2027 and 2028. Traders are debating the sustainability of the company's reliance on custom AI chip orders from major hyperscalers, with sentiment currently split between those anticipating a major breakout and those concerned about execution risks and valuation.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares are experiencing significant volatility following strong quarterly results and raised guidance, fueling a debate between investors optimistic about accelerating enterprise AI demand and skeptics concerned by a high valuation and lack of GAAP profitability.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy shares experienced significant volatility following a weak fiscal outlook and margin contraction linked to manufacturing delivery delays. While the community remains divided, many traders are focusing on the company's record $6.4 billion backlog and growing data center contract pipeline as potential catalysts for a recovery.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is trending following a third-quarter earnings report that beat expectations on both earnings and revenue, bolstered by strong AI-driven growth and a record backlog. While the company raised its future guidance, shares experienced after-hours volatility as traders weighed these strong results against management's comments regarding margin pressures and supply-chain constraints.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Shares of Ultragenyx Pharmaceutical experienced a sharp decline following the company's announcement that the Phase 3 clinical trials for its experimental bone disease drug, setrusumab, failed to meet their primary endpoints for fracture reduction. Investors and analysts expressed concern over the clinical setback and potential impact on the company's financial outlook, leading to widespread selloffs and downward revisions in price targets from multiple brokerage firms.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trading in a volatile range as investors focus on the highly anticipated Cybercab launch event in Austin, with sentiment sharply divided between optimism for autonomous driving advancements and skepticism regarding valuation and commercial execution. While many traders remain bullish on the long-term potential of robotaxis and AI-driven growth, others are actively betting on a "sell the news" event or deeper price pullbacks due to competitive and fundamental concerns.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The community is debating the potential impact of a deal to access Venezuelan oil reserves, with significant disagreement over whether it will effectively address supply constraints or merely serve as a long-term headline. Sentiment remains sharply divided, as many traders weigh this development against ongoing geopolitical tensions in the Middle East and concerns about refining capacity.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery remains the focus of market speculation as investors weigh the ongoing legal challenges to its acquisition by Paramount Skydance against the likelihood of a deal closing. While regulatory developments in the EU provide some optimism, market participants are monitoring potential antitrust hurdles from U.S. states and the impact of looming deal-related "ticking fees."

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is experiencing significant downward pressure following its latest earnings report, with the community largely debating whether the sharp sell-off is an overreaction to margin concerns or a justified adjustment given high investor expectations. While many traders see the decline as a buying opportunity, others are wary of the stock's momentum and are closely monitoring key support levels for signs of a potential rebound.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors monitor semiconductor capital expenditure and long-term demand for advanced lithography systems. Market participants are debating the company's valuation, its competitive position against emerging domestic technologies in China, and how its critical role in the AI chip supply chain will influence future financial performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

Equity

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.


Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add LXRX Stock to Your Portfolio Now

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average   - Here's What Happened

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-lexicon-pharmaceuticals-inc-stock...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High  - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - What's Next...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High  - Should You Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - Still a Buy...

• Reported GAAP EPS of -$0.07 down -800.00% YoY
• Reported revenue of $0.69M down -97.60% YoY

Lexicon Pharmaceuticals experienced a significant revenue decline and a shift to net loss in the second quarter of 2026, while navigating ongoing clinical development and complex regulatory approval requirements.

Lexicon Pharmaceuticals achieved key clinical enrollment milestones for its Phase 3 SONATA-HCM study and continues to advance ZYNQUISTA regulatory resubmission efforts alongside strategic development partnerships for its late-stage pipeline candidates.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXRX Lexicon Pharmaceuticals Inc

Fundamentals

Latest LXRX News